

Carotid artery stenting during endovascular treatment of acute ischemic stroke

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
05/12/2022	No longer recruiting	<input checked="" type="checkbox"/> Protocol
Registration date	Overall study status	<input checked="" type="checkbox"/> Statistical analysis plan
18/01/2023	Ongoing	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
04/02/2026	Circulatory System	<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

A stroke is a serious life-threatening medical condition that happens when the blood supply to part of the brain is cut off. Approximately 1 in 5 patients suffering stroke have a narrowed carotid artery. It is not yet known if early treatment to insert a tube (stent) into the narrowed artery to hold it open and prevent future stroke is worth the difficulties associated with such treatment.

Who can participate?

Patients with acute ischemic stroke with a CT-angiography-proven intracranial LVO in the anterior circulation (ICA, A1, M1 or M2) as well as an ipsilateral cervical carotid artery tandem lesion of presumed atherosclerotic origin with a stenosis >50% or an ipsilateral acute proximal internal carotid artery occlusion who are treated with EVT according to the guidelines.

What does the study involve?

Patients will be randomly allocated to receive either a carotid artery stent immediately after suffering a stroke, or to treatment as usual.

What are the possible benefits and risks of participating?

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All patients are being treated with EVT according to the local guidelines. The patients allocated to the intervention group will undergo CAS during EVT, which carries a risk of cerebral hyperperfusion syndrome and subsequent intracerebral hemorrhage. The potential benefits of immediate CAS during thrombectomy include: an improvement of cerebral blood flow during and after EVT. A second benefit is a lower risk of recurrent stroke in the first 14 days compared to the deferred treatment strategy. A third benefit of immediate CAS is that the patient does not need a second invasive treatment (carotid revascularization surgery (CEA or CAS) during the rehabilitation period which again carries some risk of complications. At last, the immediate CAS approach is likely to reduce health care costs.

Where is the study run from?

The study will be coordinated by the University Medical Center Groningen in the Netherlands and by the University Hospital Leuven in Belgium. 26 centres (9 in Belgium and 17 in the Netherlands) will participate.

When is the study starting and how long is it expected to run for?

November 2022 to November 2026

Who is funding the study?

The study is part of the COllaboration of New TReatments of Acute STroke (CONTRAST) consortium (<https://www.contrast-consortium.nl>).

The study is funded by the BeNeFIT funding members (ZonMw/KCE) (the Netherlands)

Who is the main contact?

Dr M. Uyttenboogaart, m.uyttenboogaart@umcg.nl

Contact information

Type(s)

Principal investigator

Contact name

Dr Maarten Uyttenboogaart

ORCID ID

<https://orcid.org/0000-0002-6934-4456>

Contact details

UMC Groningen

Hanzeplein 1

Groningen

Netherlands

9713 GZ

+31 50 3612400

m.uyttenboogaart@umcg.nl

Type(s)

Principal investigator

Contact name

Prof Robin Lemmens

ORCID ID

<https://orcid.org/0000-0003-3374-1502>

Contact details

UZ Leuven

Herestraat 49

Leuven

Belgium

3000

+32 16 34 42 80
robin.lemmens@uzleuven.be

Additional identifiers

ClinicalTrials.gov (NCT)

NCT06511089

Study information

Scientific Title

Carotid Artery Stenting during Endovascular treatment of acute ischemic Stroke: a randomized multicenter clinical trial in patients with acute ischemic stroke and carotid artery stenosis undergoing endovascular treatment

Acronym

CASES

Study objectives

Immediate carotid artery stenting is non-inferior compared to a deferred treatment of carotid artery stenosis/occlusion in patients with large vessel occlusion in the anterior circulation treated with endovascular thrombectomy.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 19/06/2023, Medische Ethische toetsingscommissie Erasmus MC Rotterdam (Postbus 20403000, Rotterdam, CA, Netherlands; +31 10-70 34428; metc@erasmusmc.nl), ref: NL79046.078.23 (MEC-2023-0131)

2. approved 19/06/2023, Ethics Committee Research UZ/KU Leuven (UZ Leuven, Herestraat 49, Leuven, B 3000, Belgium; +32 16 34 86 00; ec@uzleuven.be), ref: B3222022001112. (S65073)

Study design

Randomized multicenter clinical trial with a PROBE design and a non-inferiority design.

Primary study design

Interventional

Study type(s)

Efficacy, Safety, Treatment

Health condition(s) or problem(s) studied

Acute ischemic stroke in patients with large vessel occlusion in the anterior circulation and a concomitant high grade ipsilateral carotid artery stenosis or occlusion of presumed atherosclerotic origin..

Interventions

Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.

In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy or carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke).

Follow up at 90 days.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Stroke-related disability measured using the Modified Rankin Scale (mRS) Score at 90 days after stroke onset. The mRS score will be assessed by stroke research personnel by telephone interview, blinded for the treatment allocation

Key secondary outcome(s)

1. NIHSS score at 24 hours and day 5-7, or at discharge (Medical examination)
2. Adequate recanalization after EVT (TICI 2b or higher) (Review of performed imaging)
3. Final infarct volume on brain CT at 24 hours (Review of performed imaging)
4. Arterial occlusive lesion (AOL) score on CTA at 24 hours (Review of performed imaging)
5. Any stroke within 90 days (Obtained from medical records)
6. Recurrent ipsilateral TIA/ischemic stroke within 90 days
7. Carotid artery re-occlusion at 24 hours and 90 days (Review of performed imaging)
8. Mortality at 90 days (Obtained from medical records)
9. Quality of life (EQ5D-5L) questionnaire at 90 days

Completion date

15/11/2026

Eligibility

Key inclusion criteria

1. Acute ischemic stroke due to proximal intracranial occlusion in the anterior circulation (intracranial ICA, M1, proximal M2) on the CT angiography
2. Stenosis >50% according to the NASCET criteria¹⁶ or initial occlusion of the ipsilateral cervical carotid artery of presumed atherosclerotic origin on baseline CT angiography
3. Eligible for EVT according to the guidelines: EVT within 6 hours of onset or EVT between 6-24 hours after onset based on perfusion CT imaging selection (conform current guidelines)
4. Baseline National Institute of Health Stroke Scale (NIHSS) score ≥ 2
5. Age > 18 years
6. Written informed consent (deferred consent)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

99 years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Any intracranial hemorrhage
2. Cervical carotid artery stenosis or occlusion with other causes than presumed atherosclerosis (e.g. carotid artery dissection, floating thrombus, carotid web)
3. Any exclusion criterion for EVT according to the guidelines
4. Pre stroke disability (defined as a modified Rankin Scale score >2)
5. Recent gastro-intestinal or urinary tract hemorrhage (<6 weeks)
6. Recent severe head trauma (<6 weeks)
7. Recent infarction on baseline brain CT in the same vascular territory (<6 weeks)
8. Known allergy to aspirin and/or clopidogrel
9. Pregnancy

Date of first enrolment

19/06/2023

Date of final enrolment

29/11/2025

Locations

Countries of recruitment

Belgium

Netherlands

Study participating centre

University Medical Center Groningen

Hanzeplein 1
Groningen
Netherlands
9713 GZ

Study participating centre

University Hospital Leuven

Herestraat 49

Leuven

Belgium

3000

Study participating centre

Amsterdam University Medical Center

Meibergdreef 9

Amsterdam

Netherlands

1105 AZ

Study participating centre

Erasmus Medical Center Rotterdam

Dr. Molewaterplein 40

Rotterdam

Netherlands

3015 GD

Study participating centre

Leiden University Medical Center

Albinusdreef 2

Leiden

Netherlands

2333 ZA

Study participating centre

Maastricht University Medical Center

P. Debyelaan 25

Maastricht

Netherlands

6229 HX

Study participating centre

Utrecht University Medical Center

Heidelberglaan 100

Utrecht
Netherlands
3584 CX

Study participating centre

Isala Zwolle
Dokter van Heesweg 2
Zwolle
Netherlands
8025 AB

Study participating centre

Haaglanden Medisch Centrum
Lijnbaan 32
Den Haag
Netherlands
2512 VA

Study participating centre

Haga Medisch Centrum
Els Borst-Eilersplein 275
Den Haag
Netherlands
2545 AA

Study participating centre

Rijnstate ziekenhuis
Wagnerlaan 55
Arnhem
Netherlands
6815 AD

Study participating centre

Catharina Ziekenhuis Eindhoven
Michelangelolaan 2
Eindhoven
Netherlands
5623 EJ

Study participating centre

Amphia Ziekenhuis
Molengracht 21
Breda
Netherlands
4818 CK

Study participating centre

Medisch Spectrum Twente
Koningstraat 1
Enschede
Netherlands
7512 KZ

Study participating centre

Noordwest Ziekenhuisgroep
Wilhelminalaan 12
Alkmaar
Netherlands
1815 JD

Study participating centre

Albert Schweitzer ziekenhuis
Albert Schweitzerplaats 25
Dordrecht
Netherlands
3318 AT

Study participating centre

Radboud University Medical Center
Geert Grootplein Zuid 10
Nijmegen
Netherlands
6525 GA

Study participating centre

AZ Sint Jan
Ruddershove 10
Brugge
Belgium
8000

Study participating centre

Hopital Erasme

Lenniksebaan 808

Bruxelles

Belgium

1070

Study participating centre

Universitair Ziekenhuis Gent

Corneel Heymanslaan 10

Gent

Belgium

9000

Study participating centre

Civil Hospital Marie Curie

Chau. de Bruxelles 140

Charleroi

Belgium

6042

Study participating centre

UZ Brussel

Laarbeeklaan 101

Jette

Belgium

1090

Study participating centre

AZ Groeninge

President Kennedylaan 4

Kortrijk

Belgium

8500

Study participating centre

CHU Liège

Avenue de l'Hôpital 1

Liège
Belgium
4000

Study participating centre
Universitair Ziekenhuis Antwerpen
Drie Eikenstraat 655
Edegem
Belgium
2650

Study participating centre
Elisabeth Tweesteden Ziekenhuis
Hilvarenbeekse Weg 60
Tilburg
Netherlands
5022 GC

Study participating centre
UCL Saint-Luc
Hippokrateslaan 10
Brussel
Belgium
1200

Sponsor information

Organisation
University Medical Center Groningen

ROR
<https://ror.org/03cv38k47>

Funder(s)

Funder type
Government

Funder Name

BeNeFIT call funding member (ZonMw and KCE)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request after central review by the "Data Access Writing Committee" from the CONTRAST consortium.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>		16/02/2025	04/02/2026	Yes	No
<u>Statistical Analysis Plan</u>	version 1.0	22/01/2025	04/02/2026	No	No
<u>Study website</u>	Study website	11/11/2025	11/11/2025	No	Yes